Correction: MicroRNAs Expression in the Ileal Pouch of Patients with Ulcerative Colitis Is Robustly Up-Regulated and Correlates with Disease Phenotypes

Ben‐Shachar, Shay; Yanai, Henit; Horev, Hadas Sherman; Elad, Hofit; Baram, Liran; Isakov, Ofer; Tulchinsky, Hagit; Pasmanik-Chor, Metsada; Shomron, Noam; Dotan, Iris

doi:10.1371/journal.pone.0165220

Cited by 2 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-223 was also identified as a fecal marker in a study by Schönauen et al [ 25 ], in addition to miR-155 and miR-16. A summary of miRNAs found altered in each disease is shown in Table 1 [ 55 - 61 ] and Table 2 [ 62 - 69 ].…”

Section: Inflammatory Bowel Disease and Microrna Expressionmentioning

confidence: 99%

MicroRNA expression in inflammatory bowel disease-associated colorectal cancer

Grillo

Quaglio

Beraldo

et al. 2021

WJGO

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are non-coding RNA molecules composed of 19–25 nucleotides that regulate gene expression and play a central role in the regulation of several immune-mediated disorders, including inflammatory bowel diseases (IBD). IBD, represented by ulcerative colitis and Crohn’s disease, is characterized by chronic intestinal inflammation associated with an increased risk of colorectal cancer (CRC). CRC is one of the most prevalent tumors in the world, and its main risk factors are obesity, physical inactivity, smoking, alcoholism, advanced age, and some eating habits, in addition to chronic intestinal inflammatory processes and the use of immunosuppressants administered to IBD patients. Recent studies have identified miRNAs associated with an increased risk of developing CRC in this population. The identification of miRNAs involved in this tumorigenic process could be useful to stratify cancer risk development for patients with IBD and to monitor and assess prognosis. Thus, the present review aimed to summarize the role of miRNAs as biomarkers for the diagnosis and prognosis of IBD-associated CRC. In the future, therapies based on miRNA modulation could be used both in clinical practice to achieve remission of the disease and restore the quality of life for patients with IBD, and to identify the patients with IBD at high risk for tumor development.

show abstract

Section: Inflammatory Bowel Disease and Microrna Expressionmentioning

confidence: 99%

MicroRNA expression in inflammatory bowel disease-associated colorectal cancer

Grillo

Quaglio

Beraldo

et al. 2021

WJGO

View full text Add to dashboard Cite

show abstract

Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases

Ryvchin

Dubinsky

Rabinowitz

et al. 2021

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and Aims Bacterial urease is a major virulence factor of human pathogens, and murine models have shown that it can contribute to the pathogenesis of inflammatory bowel diseases [IBD]. Methods The distribution of urease-producing bacteria in IBD was assessed using public fecal metagenomic data from various cohorts, including non-IBD controls (n = 55), patients with Crohn’s disease (n = 291), ulcerative colitis (n = 214), and patients with a pouch (n = 53). The ureA gene, and the taxonomic markers gyrA, rpoB and recA were used to estimate the percentage of urease producers in each sample. Results Levels of urease producers in patients with IBD and non-IBD controls were comparable. In non-IBD controls and most IBD patients, urease-producers were primarily acetate producing genera such as Blautia and Ruminococcus. A shift in the type of the dominant urease producers towards Proteobacteria and Bacilli was observed in a subset of all IBD subtypes, which correlated with fecal calprotectin levels in one cohort. Some patients with IBD had no detectable urease producers. In patients with a pouch the probiotic-associated species Streptococcus thermophilus was more common as a main urease producer than in other IBD phenotypes, and it generally did not co-occur with other Bacilli or with Proteobacteria. Conclusions Unlike all non-IBD controls, patients with IBD often showed a shift towards Bacilli or Proteobacteria or a complete loss of urease production. Probiotics containing the species S. thermophilus may have a protective effect against colonization by undesirable urease-producing bacteria in a subset of patients with a pouch.

show abstract

Correction: MicroRNAs Expression in the Ileal Pouch of Patients with Ulcerative Colitis Is Robustly Up-Regulated and Correlates with Disease Phenotypes

Cited by 2 publications

References 1 publication

MicroRNA expression in inflammatory bowel disease-associated colorectal cancer

MicroRNA expression in inflammatory bowel disease-associated colorectal cancer

Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases

Contact Info

Product

Resources

About